Sol-Gel Technologies Ltd.
NASDAQ · us_market
No AI insight generated yet for this ticker.
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat olmsted syndrome. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-21upcoming | -3.33 | — | — |
| 2026-05-28 | -2.86 | -1.31 | +54.20% |
| 2026-05-01 | 0.39 | — | — |
| 2026-03-19 | 0.39 | -1.06 | -371.79% |
| 2025-11-20 | -2.09 | -2.13 | -1.91% |
| 2025-08-15 | -0.70 | 4.17 | +695.71% |
| 2024-11-15 | -0.50 | -0.10 | +80.00% |
| 2024-08-16 | -1.90 | 0.70 | +136.84% |
| 2024-05-20 | -1.60 | -2.30 | -43.75% |
| 2024-03-13 | -1.75 | -1.70 | +2.86% |
| 2023-11-09 | -2.30 | -2.10 | +8.70% |
| 2023-08-10 | -2.55 | -2.20 | +13.73% |
| 2023-05-12 | -2.15 | -4.10 | -90.70% |
| 2023-03-10 | -1.25 | -2.50 | -100.00% |
| 2022-11-10 | -0.65 | -1.50 | -130.77% |
| 2022-08-04 | -0.97 | -0.10 | +89.66% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| SLGL | -2.31% | -16.45% | +75.27% | +920.17% |
| XLV | +2.97% | -4.83% | -3.44% | +12.62% |
| Alpha (stock − sector) | -5.28% | -11.62% | +78.72% | +907.55% |